Trusted Resources: Education
Scientific literature and patient education texts
Nusinersen: A Review in 5q Spinal Muscular Atrophy
source: CNS drugs
year: 2021
authors: Hoy SM
summary/abstract:Survival motor neuron 1 (SMN1), located on chromosome 5q, encodes the survival motor neuron (SMN) protein. A deletion or mutation in SMN1 results in a rare neuromuscular disorder: 5q spinal muscular atrophy (SMA). In such patients, SMN protein production relies solely on SMN2. Nusinersen (Spinraza) is a modified antisense oligonucleotide approved for the treatment of 5q SMA. Administered intrathecally, it modifies SMN2 pre-messenger RNA splicing, thereby increasing full-length SMN protein levels. Interim analyses from an ongoing phase II study suggest substantial clinical benefits with nusinersen initiation in presymptomatic patients. In phase III studies, nusinersen achieved significant and/or clinically relevant improvements in motor function in symptomatic patients with infantile- and later-onset 5q SMA, and significantly improved event-free survival and overall survival in patients with infantile-onset 5q SMA. Longer term (up to a median of ≈ 6 years of available data), motor function was maintained or improved in symptomatic patients. Nusinersen had a favourable safety profile in clinical studies in presymptomatic and symptomatic patients. Real-world experience supports the effectiveness, safety and tolerability of nusinersen in symptomatic patients of all ages. Thus, nusinersen remains an important treatment option among a broad range of 5q SMA patients.
organization: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. [email protected].DOI: 10.1007/s40263-021-00878-x
read more
Related Content
-
Comparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular AtrophySpinal Muscular Atrophy (SMA) is a genet...
-
SMA and Nusinersen (Spinraza) the Story so farhttps://slideplayer.com/slide/14664651/...
-
Carrier Screening for Genetic ConditionsCarrier screening is a term used to desc...
-
Biogen Announces New Updates Across Its SMA Research Program at 2022 MDA ConferenceBiogen Inc. announced new data and updat...
-
Your Guide to Spinal Muscular Atrophyhttps://simedhealth.com/sites/default/fi...
-
Spinal Muscular Atrophy: From Rags to RichesThe aim of this paper is to provide a sh...
-
Baby Among the First to Receive Gene Therapy for Spinal Muscular Atrophy After FDA Approvalhttps://www.youtube.com/watch?v=adc6vztu...